Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
RESEARCH TOOLSreports
Holding NAUT?
Track your performance easily
NAUT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.19 - $3.45
Previous Close$2.24
Volume68.42K
Average Volume (3M)87.85K
Market Cap
$281.26M
Enterprise Value$172.22M
Total Cash (Recent Filing)$140.61M
Total Debt (Recent Filing)$31.57M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Feb 20, 2025EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding125,563,965
10 Day Avg. Volume159,022
30 Day Avg. Volume87,846
Standard Deviation0.15
R-Squared0.16
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.31
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.72
Forecast
1Y Price Target
$5.00Price Target Upside113.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Nautilus Biotechnolgy News
PremiumCompany Announcements
Nautilus Biotechnology Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is NAUT a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Commercial StrategyManagement expressed a high degree of confidence in being on a path to a full commercial launch of their PriSM technology for broadscale discovery.
Financial ManagementPrudent cost management enables cash runway to extend into 2027.
Technological DevelopmentProgress towards developing a differentiated proteomics offering and continued cash management remains encouraging.
Bears Say
Commercial LaunchStock upside likely limited pending commercial launch.
Internal MilestonesBehind on internal milestones towards being able to quantify a significant number of proteins from a complex sample.
Product DevelopmentTimelines slipped again given ongoing efforts to develop commercial-ready probes for its single molecule proteome tech.
---
Ownership Overview
42.95% Insiders
3.76% Mutual Funds
41.86% Other Institutional Investors
6.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $2.19 and its highest was $3.45 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Currently, no data Available
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Feb 20, 2025 which is in 91 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Oct 29, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.035.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -$0.16.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 125,563,965 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went down -1.423%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Among the largest hedge funds holding Nautilus Biotechnolgy’s share is Perceptive Advisors LLC. It holds Nautilus Biotechnolgy’s shares valued at 36M.
---
Nautilus Biotechnolgy Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (113.68% Upside)
$5.00 (113.68% Upside)
Insider Transactions
Sold Shares
Worth $234.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.79%
12-Months-Change
Fundamentals
Return on Equity
-28.04%
Trailing 12-Months
Asset Growth
-18.42%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
ARYA Sciences Acquisition Corp III is a blank check company.
---
NAUT Company Deck
---
NAUT Earnings Call
Q3 2024
0:00 / 0:00
---
NAUT Stock 12 Month Forecast
Average Price Target
$5.00
▲(113.68% Upside)
Technical Analysis
Best Analysts Covering NAUT
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-5.00%
assigned a buy rating 22 days ago
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -5.00% per trade.
---